In vitro diagnostic (IVD) testing constitutes less than 1% of the global US$2,500 billion healthcare industry, but plays the decisive role in most medical decisions, and helps save across the entire healthcare spectrum. Driven by clinical, social and economic pressures coupled with new technologies and IT capabilities, IVD industry is shifting to rapid diagnostic testing (RDT) to minimise the requirement of technical expertise and analysis time. Capnosis exploits a novel nucleic acid- based technology to provide superior RDT products for unmet markets. Our tests efficiently address the two most significant challenges in public healthcare: cost and safety.

Hang TT Le